SOURCE
Pammolli and Riccaboni, 2001, based on BID, University of Siena
 |
|
| Home | Encyclopedia | Statistics | Countries A-Z | Flags | Maps | Education | Forum | FAQ | About |
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
del.icio.us| COMMENTARY |
|
Halesuhtem 30th June 2010 |
It would be nice if this included all the countries in europe. And even better if they included the rest of the world. Isnt england leading in biotech in europe? Strange i dont find england. Hungary should also be included, with 77+- firms. czech and poland is 40+ too. Germany is probably not nr 1 after being compared with usa, naturally because of its size. I suspect that this wont give a realistic picture of biotechnology firms in europe, nor the world. |
|
tammy 11th January 2006 |
why are there only biotechnology stats for Europe? where is the US, Asia, etc.? funding? information about R&D expenditure by country would be great as well. very difficult to find this information. |
|
mazambne 16th November 2005 |
I'm a mozambican sudent and doig my licence thesis in economics. I'd like to get statistics about Sugarcane industry in Mozambique. |
|
Ian Graham Staff Editor 20th March 2005 |
Cuba is the largest medicine exporter in Latin America, with more than 50 client nations. The main markets for Cuba’s medicines are former Soviet states and third world countries. Cuban medicines are popular because they are cheaper than those produced in developed countries, though some cannot be sold in countries that respect patent laws. In 1994, Cuba exported $110 million worth of medical supplies. In 1995, this figure rose to $125 million. Cuban biotechnology researchers have been granted more than 100 patents, include 26 in the United States. In October 1999 SmithKline Beecham, announced details of an agreement to test and market a Cuban meningitis vaccine, first in Europe and eventually in the U.S. Cuban biotechnology research is responsible for drugs such as recombinant streptokinase, a "clot-buster" for heart attack victims produced at a fraction of the cost of similar medicines in developed countries. |
There are 2 more (non-authoritative) comments on this page
|
Share your thoughts, questions and commentary here
|
Lesson Plans | Student Area | Student FAQ | Reviews | Press Releases |
Feeds |
Contact© Copyright NationMaster.com 2003-2013. All Rights Reserved. Usage implies agreement with terms, 1022, m